The data are held in a public repository: <https://doi.org/10.5281/zenodo.1405531>.

Introduction {#sec007}
============

The most common chronic complication of herpes zoster (HZ; shingles) is postherpetic neuralgia (PHN), a persistent neuropathic pain that occurs after the acute HZ infection. HZ is considered a significant public health problem, due to its increasing incidence along with the ageing population\[[@pone.0217335.ref001]\] and its substantial impact on patient quality of life, in the acute and chronic phases\[[@pone.0217335.ref002]\]. Moreover, HZ was recently associated with greater risk for cerebrovascular and cardiac events shortly after the acute infection occurs\[[@pone.0217335.ref003]\].

Reactivation of varicella zoster virus (VZV), a double-stranded DNA virus responsible for chickenpox, causes HZ. This virus remains dormant within the dorsal root ganglion, and its reactivation, typically in adults older than 50 years\[[@pone.0217335.ref004]\], leads to unilateral, dermatomal, and painful skin eruptions. The reactivation of VZV is associated with the age-related decrease of cellular immunity to VZV and with impaired cellular immune function \[[@pone.0217335.ref005]\].

Before the introduction of the universal varicella immunization, the seroprevalence of VZV was estimated to be higher than 95% in people older than 65 year, across 16 European countries according to a recent systematic review\[[@pone.0217335.ref006]\]; many people are therefore at risk for developing HZ\[[@pone.0217335.ref007]\]. The incidence of HZ increases with age. The estimated overall incidence is 3.4 to 4.82 per 1000 person-years and increases up to 11 per 1000 person-years in patients aged over 80 years\[[@pone.0217335.ref007]\]. The lifetime risk ranges between 25% and 30% but is up to 50% for individuals older than 80 years\[[@pone.0217335.ref007]\].

Estimates for the risk of developing PHN among individuals with HZ range from 5% to more than 30%\[[@pone.0217335.ref008]\], but there are disagreements about the incidence and prevalence of PHN because there is no universally accepted definition. Thus, a compressive review reported the incidence of PHN was 3.9 to 42.0/100,000 person-years\[[@pone.0217335.ref009]\]. Previous studies have defined PHN according to the severity of pain (≥3 or 4 on a 10-point Likert scale)\[[@pone.0217335.ref010]\] or duration (pain persisting for 30, 90, 120, or 180 days)\[[@pone.0217335.ref011]\]. The main risk factors for PHN are older age, greater acute pain, more widespread rash, presence of prodromal pain, and ophthalmic involvement\[[@pone.0217335.ref008]\].

Patients with PHN may describe their pain as constant or intermittent, and as burning, aching, throbbing, stabbing, or shooting. Some patients also report allodynia, hyperalgesia and dysesthesia\[[@pone.0217335.ref011]\]. This long-lasting and debilitating pain may persist for months to years and is often refractory to pharmacological therapies\[[@pone.0217335.ref008]\].

PHN negatively affects all four health domains---physical, social, functional and psychological\[[@pone.0217335.ref002]\] and is associated with significant direct and indirect healthcare costs\[[@pone.0217335.ref012]\]. Moreover, PHN is related with a considerable burden on patients, caregivers, the healthcare system and employers\[[@pone.0217335.ref007]\].

Researchers and clinicians have proposed many therapies for prevention of PHN, including pharmacological therapies (such as antivirals, amitriptyline, and pregabalin), interventional procedures (epidural and sympathetic nerve blocks), VZV vaccination, and complementary and alternative therapies (such us acupuncture and electrical nerve stimulation). A Cochrane systematic review reported that antivirals, such as acyclovir, may decrease the severity of acute HZ pain at 1 month relative to placebo, but had no significant effect on prevention of PHN \[[@pone.0217335.ref013]\]. The same review highlighted the need for more studies of valacyclovir and famciclovir and of different subgroups of patients. Another study reported that corticosteroids given during the acute phase of HZ provided no benefit in preventing PHN \[[@pone.0217335.ref014]\]. There is some evidence that amitriptyline (25 mg per day for 3 months) may decrease the incidence of PHN \[[@pone.0217335.ref015]\], but further research is needed to confirm the results of this single study.

The only established method for prevention of PHN is the HZ vaccine \[[@pone.0217335.ref010]\], but the effectiveness of the live attenuated vaccine seems to decline over time \[[@pone.0217335.ref016]\]. A new recombinant zoster vaccine (Zostavax) was recently approved for adults who are 50 or more years-old, and this new vaccine seems more effective for prevention of HZ and PHN \[[@pone.0217335.ref017]\].

Gabapentin is an anticonvulsant initially developed and approved as adjunctive therapy for treatment of partial seizures, often used for the treatment of neuropathic pain\[[@pone.0217335.ref018]\]. It is an analogue of gamma aminobutyric acid and binds to the α~2~-δ site of voltage-dependent calcium channels, thereby reducing neurotransmitter release \[[@pone.0217335.ref018]\]. A previous study reported that gabapentin reduced acute herpetic pain and delayed postherpetic pain in mice \[[@pone.0217335.ref019]\]. Studies in humans demonstrated gabapentin was beneficial for the treatment of chronic neuropathic pain and might also reduce allodynia and hyperalgesia\[[@pone.0217335.ref020]\]. The European consensus-based guideline on the management of HZ recommends that gabapentin may be added to analgesics for treatment of HZ infection if moderate or severe pain is present \[[@pone.0217335.ref021]\].

The objective of this study of patients older than 50 years with moderate or severe pain from HZ was to assess the efficacy of gabapentin added to the usual treatment (valacyclovir and analgesics as needed) on reducing acute pain and preventing PHN at 12 weeks.

Materials and methods {#sec008}
=====================

Design and setting {#sec009}
------------------

A full description of the research protocol was published previously\[[@pone.0217335.ref022]\]. This was a multicenter, parallel, randomized, double-blind, placebo-controlled trial of patients from 17 primary health care centers in Mallorca (Spain) that was conducted from February 2014 to January 2017. This study followed the principles outlined in the Declaration of Helsinki. The study protocol was also approved by the Primary Care Research Committee of the Balearic Ethical Committee of Clinical Research (IB 1857/12), and the Spanish Agency on Drugs and Medical Devices (Agencia Española de Medicamentos y Productos Sanitarios). The trial was registered on ISRCTN (Registry identifier: ISRCTN79871784) on May 2, 2013 (<http://www.isrctn.com/ISRCTN79871784>). Before inclusion in the trial, each patient signed a written informed consent document.

Patients {#sec010}
--------

All patients presenting with acute herpetic rash at one of the participating centers were assessed and referred to the collaborating general practitioner (GP), who determined if the inclusion criteria were satisfied. If so, the patient was asked to sign an informed consent document. All included patients were older than 50 years, had uncomplicated HZ presenting within the first 72 h of vesicle formation, and had an average pain score of at least 4 of 10 on a visual analogue scale (VAS) before therapy (**[Fig 1](#pone.0217335.g001){ref-type="fig"}**).

![Study design and patient disposition (CONSORT flow diagram).](pone.0217335.g001){#pone.0217335.g001}

Patients were excluded if they were taking gabapentin or a tricyclic antidepressant; had evidence of cutaneous or visceral dissemination or ocular involvement; had a history of intolerance or hypersensitivity to any active components or excipients in the study drugs; had severe hepatic impairment or impaired renal function; received cytotoxic drugs or immunosuppressive therapy within the previous 3 months (e.g., long-term systemic corticosteroids); were diagnosed with any immune dysfunction; used immunomodulatory medications (including interferon) within the previous 4 weeks; or received a VZV vaccine.

Treatment {#sec011}
---------

Participants were randomly allocated to receive gabapentin or placebo by use of a computer-generated randomization list in blocks of six. The randomization and allocation process were described in a previous publication\[[@pone.0217335.ref022]\]. The participants, the collaborating GP, the research staff, and the investigators who assessed outcomes were all blinded to treatment allocations. At the final visit, to assess the effectiveness of blinding, the patients were asked to guess whether they received the treatment or placebo. The trial period was 12 weeks, and the patients were scheduled for 5 visits (baseline, week-1, -4, -6, and -12). At baseline, sociodemographic data (age, sex, weight, and height) and clinical data (significant medical history, concomitant use of other medications) were collected. The rash localization, pain intensity, quality of life and sleep patterns were also recorded.

All participants received 1000-mg caplets of valacyclovir hydrochloride 3 times daily for 7 days, and an analgesic according to the World Health Organization three-step pain relief ladder (nonopioids, mild opioids, then strong opioids) \[[@pone.0217335.ref023]\]. At the baseline visit, patients received one bottle of 300-mg gabapentin pills or matching placebos.

The treatment period was 5 weeks. Gabapentin was initiated at 300 mg/day at breakfast, and the dose increased by 300 mg/day up to a ceiling dose of 1800 mg/day by day 7 (**[Fig 2](#pone.0217335.g002){ref-type="fig"}**). The dose was increased regardless of whether efficacy was achieved at a lower dose. Among patients who developed adverse effects, the dose was reduced to the previously tolerated level. Gabapentin (at 1800 mg/day or the optimal dose established during the titration period) was maintained for 3 weeks and was followed by dose-tapering for a maximum of 1 week. Patients receiving the placebo received the same dose escalation and the same number of capsules. Patients were not allowed to receive tricyclic antidepressants or systemic corticosteroids during the trial.

![Dose titration scheme during the 1^st^ week of the study.](pone.0217335.g002){#pone.0217335.g002}

Excerpt of the study medication dose titration scheme based on a dose of 1800mg/day. Treatment was maintained for 3 weeks, followed by a 1 week of dose tapering.

Outcome measures {#sec012}
----------------

The primary outcome was the efficacy of gabapentin on reducing PHN, based on a 10-point VAS in which 0 indicated no pain and 10 indicated the worst possible pain. PHN was considered present for any score above 0 at week-12.

The secondary outcome measures were:

1.  *(i)* moderate-severe pain (VAS ≥ 4) at week-12;

2.  *(ii)* neuropathic pain based on a validated Spanish version of the DN4 questionnaire (Doleur Neuropathique) \[[@pone.0217335.ref024]\] at baseline and week-12;

3.  \(iii\) any pain (VAS score \> 0) at week-4 and week-6;

4.  *(iv)* 50% reduction of pain relative to baseline\[[@pone.0217335.ref025]\], measured using a VAS;

5.  *(v)* quality of life based on the ShortForm-12 (SF-12) \[[@pone.0217335.ref026]\] at baseline, week-4, and week-12;

6.  *(vi)* sleep interference based on the Medical Outcomes Study Sleep Scale (MOS-Sleep) \[[@pone.0217335.ref027]\] at baseline, week-4, and week-12;

7.  *(vii)* patient global impression of change scale (PGIC) \[[@pone.0217335.ref028]\] score at week-12;

8.  *(viii)* analgesic consumption (recorded at every visit);

9.  and *(ix)* safety and adverse effects (recorded at every visit).

Statistical analysis {#sec013}
--------------------

An initial estimate indicated that a sample size of 134 would be required for a statistical power of 80% and detection of a difference of at least 25% in the incidence of PHN. Thus, a 12-month recruitment period was planned, with an anticipated loss to follow-up of 20%. Primary analyses were performed on an intention-to-treat basis. All randomized patients, regardless of whether they received the treatment or were lost to follow up, were analyzed by use of multiple imputation methods that considered treatment group, age, sex, HZ location, and VAS pain score at baseline.

Logistic regression models, which adjusted for age, sex, and HZ location, were performed to analyze the effectiveness of gabapentin treatment by measurement of *(i)* number of patients reporting any pain (VAS \> 0) at week-12; *(ii)* pain ≥ 4 on the VAS or based on DN-4 score, *(iii)* any pain (VAS \> 0) at week-6; and *(iv)* pain reduction of 50% or more at week-12. Between-group comparisons of sleep quality (measured by the MOS-Sleep questionnaire) and quality of life (measured by the SF-12 questionnaire) at week-12 were analyzed by Student's *t*-test. All treatment effects were considered significant for a two-sided *p*-value of 0.05.

The results of analyses according to intention to treat and per protocol were compared. The per protocol analysis included 2 different analyses: effectiveness of gabapentin among patients completing the trial, and effectiveness of gabapentin among those taking at least 300 mg gabapentin or placebo per day.

The effectiveness of patient blinding in each treatment group was evaluated using the James blinding index, applying the equation provided by the authors\[[@pone.0217335.ref029]\]. This index is a variation of the kappa coefficient and ranges between 0 to 1, in which 0 indicates total absence of blinding, 1 indicates complete blinding, and 0.5 indicates completely random \[[@pone.0217335.ref030]\]. The participants were asked to guess to which group they were designated, by choosing one of the following answers: (i). gabapentin or (ii). placebo or (iii). \"don't know\". Successful blinding was considered if the upper bound of the confidence interval (CI) of the index was above 0.5.

We performed a between-group comparisons of reported pain at week-1, -4, -6, and -12, the treatment groups were compared using an analysis of covariance, adjusted for age, sex, and HZ location. A Chi-square test was used for analysis of PGIC scores and presence of optimal sleep (yes/no) on the MOS-Sleep scale.

Results {#sec014}
=======

The 29 participating GPs initially screened 128 eligible patients (**[Fig 1](#pone.0217335.g001){ref-type="fig"}**). Ninety-eight consenting patients were ultimately randomized, 50 to the intervention group and 48 to the placebo group. After randomization, 15 patients (15.3%) were loss to follow up (10 in the gabapentin group and 5 in the placebo group) and 7 patients (7.14%) withdrew consent (6 in the gabapentin group and 1 in the placebo group). One patient randomized to the gabapentin group was excluded from the analysis, for not meeting inclusion criteria. Adverse effects from gabapentin were responsible for 3.1% of the patient losses (3 of 6 patients who withdrew consent).

The two groups had similar demographic and clinical characteristics at baseline ([Table 1](#pone.0217335.t001){ref-type="table"}). Overall, the mean patient age at enrolment was 65 years, 54.1% of the patients complained of moderate pain (4 to 6.9 on a VAS), and 45.9% complained of severe pain (7 to 10 on a VAS).

10.1371/journal.pone.0217335.t001

###### Baseline characteristics of patients in the two groups.
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  ---------------------------------------------------------------------------------------
                                                  Gabapentin (n = 49)   Placebo(n = 48)
  ----------------------------------------------- --------------------- -----------------
  **Age (years)**                                 65.1±11.4             66.0±11.1

      • \<65                                      27/49 (55.1)          23/48 (47.9)

      • 65--84                                    20/49 (40.8)          25/48 (52.1)

      • \>85                                      2/49 (4.1)            0/48 (0)

  Women                                           28/48 (58.3)          30/48 (62.5)

  BMI (kg/m^2^)                                   28.1±4.7              27.3±5.7

  **HZ Location**                                                       

      • Thorax                                    26/49 (53.1)          19/48 (39.6)

      • Abdomen                                   7/49 (14.3)           7/48 (14.6)

      • Extremities                               9/49 (18.4)           10/48 (20.8)

      • Other                                     7/49 (14.3)           12/48 (25.0)

  **Pain VAS**                                    **Mean (SD)**\        **Mean (SD)**\
                                                  7.0±1.8               6.6±1.8

  **SF-12**                                       **Mean (SD)**         **Mean (SD)**

      • Physical functioning                      45.6±12.1             48.9±10.6

      • Role Physical                             26.9±3.6              27.6±3.4

      • Role emotional                            20.1±4.5              20.2±4.3

      • Mental Health                             48.3±11.4             51.1±11.7

      • Bodily pain                               50.2±11.7             48.2±11.5

      • General Health                            41.8±11.2             43.3±11.2

      • Vitality                                  53.1±11.7             54.5±11.5

      • Social functioning                        50.2±9.0              49.0 ±11.0

      • Summary Scale Physical                    44.3±9.8              45.1±7.6

      • Summary Scale Mental                      40.9±8.7              41.7±9.8

  **MOS- Sleep**                                  **Mean (SD)**         **Mean (SD)**

      • Sleep disturbance                         33.7±26.5             34.6±30.4

      • Snoring                                   58.5±38.0             43.8±38.3

      • Awakening with short breath or headache   11.2±20.5             6.5±20.5

      • Sleep adequacy                            68.3±32.6             73.0±28.0

      • Day-time somnolence                       31.9 ±19.9            31.9±22.4

      • Sleep Problems Index                      25.7±18.8             24.2±22.9

  **MOS Sleep: optimal sleep**                    21/43 (48.8)          23/41 (56.1)
  ---------------------------------------------------------------------------------------

Abbreviations: BMI: Body Mass Index; VAS: visual analogic scale; SD: standard deviation; SF-12: Short-Form 12; MOS- Sleep: Medical Outcomes Study.

The maximum allowed daily dosage of gabapentin (1800 mg) was achieved in 9 of 33 patients (27.3%). The mean adherence was 97.5% in the placebo group and 74.8% in the gabapentin group. The major side effects in the gabapentin group were dizziness (10 patients), somnolence (8 patients), and abdominal pain (5 patients); the major side effects in the placebo group were also dizziness (4 patients), somnolence (4 patients), and abdominal pain (2 patients).

Primary outcomes {#sec015}
----------------

At week-12, 10 patients overall reported at least some pain (VAS \> 0), 4 in the placebo group and 6 in the gabapentin group ([Table 2](#pone.0217335.t002){ref-type="table"}). This difference was not statistically significant, p-value = 0.144, OR (95% confidence interval \[95%CI\]) = 2.59(0.59--11.28).

10.1371/journal.pone.0217335.t002

###### Postherpetic neuralgia pain scores at week-12 (primary outcomes) and week-6 (secondary outcome) in the two groups.
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  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \                          Gabapentin\    Placebo\      OR (95% CI)[\*](#t002fn002){ref-type="table-fn"}   p-Value   Gabapentin\     Placebo       OR (95% CI)[\*](#t002fn002){ref-type="table-fn"} \>300 mg/day\   p-Value   ITT analysis\       p-Value
                             n/N (%)        n/N (%)                                                                    \>300 mg/day\                 n/N (%)                                                                    Imputed OR\         
                                                                                                                       n/N (%)                                                                                                  (95% CI)            
  -------------------------- -------------- ------------- -------------------------------------------------- --------- --------------- ------------- ---------------------------------------------------------------- --------- ------------------- ---------
  **Primary outcomes**                                                                                                                                                                                                                              

  Pain VAS \> 0 at week-12   6/33 (18.2)    4/42 (9.5)    2.59 (0.59--11.28)                                 0.144     3/24 (12.5)     3/32 (9.4)    1.58 (0.25--10.02)                                               0.627     2.61 (0.43--15.8)   0.283

  Pain VAS ≥ 4 at week-12    4/33 (12.1)    0/42 (0)      N/A                                                N/A       2/24 (8.3)      0/32 (0)      N/A                                                              N/A       N/A                 N/A

  DN-4 ≥4 at week-12         4/32 (12.5)    3/37 (8.1)    1.55 (0.28--8, 61)                                 0.827     2/24(8.3)       3/29 (10.3)   0.74 (0.10--5.30)                                                0.740     1.54 (0.23--10.4)   0.735

  **Secondary outcome**                                                                                                                                                                                                                             

  Pain VAS \> 0 at week-6    10/33 (30.3)   6/40 (15.0)   1.94 (0.57--6.53)                                  0.287     6/24 (25.0%)    3/32 (9.4)    2.8 (0.56--14.56)                                                0.205     2.42 (0.63--9.25)   0.188
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: OR: odd ratio; 95% CI: 95% confidence interval; ITT: intention to treat; VAS: visual analogic scale; DN4: Doleur Neuropathique in 4 Questions.

\*Adjusted by age, sex, and herpes zoster location.

Three patients in the gabapentin group and no patients in the placebo group reported pain greater than 4 on the VAS atweek-12.

The two groups had no significant difference in the incidence of neuropathic pain, based on the DN-4 questionnaire at week-12 (placebo group: 10.8%; gabapentin group: 12.5%). Moreover, most patients did not report any pain on the pain VAS at week-12 ([Table 3](#pone.0217335.t003){ref-type="table"}). For patients reporting pain at week-12, most reported only mild pain, and only 3 patients reported moderate pain (4 to 6.9 on a VAS). Gabapentin had no effect on average HZ pain at any time ([Table 3](#pone.0217335.t003){ref-type="table"}). Although both groups experienced reductions in pain over time, this change was larger and statistically significant in the placebo group at week-4, -6, and -12.

10.1371/journal.pone.0217335.t003

###### Average herpes zoster pain score at week-1, -4, -6, and -12 in the two groups.
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             Gabapentin       Placebo           Difference        
  ---------- ---------------- ----------------- ----------------- -----------
  1 week     3.9 (3.1--4.8)   3.5 (2.6--4.3)    0.5 (-0.7--1.6)   0.451
  4 weeks    2.2 (1.4--2.9)   0.8 (0.1--1.5)    1.4 (0.3--2.4)    **0.009**
  6 weeks    1.2 (0.7--1.7)   0.3 (-0.1--0.8)   0.9 (0.2--1.6)    **0.014**
  12 weeks   0.8 (0.4--1.3)   0.1 (-0.3--0.5)   7.8 (1.7--13.9)   **0.013**

Abbreviations: 95%CI: 95% confidence interval; VAS: visual analogic scale.

Response rate {#sec016}
-------------

At 6 weeks, 10 patients in the gabapentin group and 6 in the placebo group reported some pain (VAS \> 0). This difference was not statistically significant ([Table 2](#pone.0217335.t002){ref-type="table"}). Comparison of pain at baseline and week-12 indicated most patients in the gabapentin group (30/33) had a 50% or greater reduction of pain, but all 42 patients in the placebo group had a 50% or greater reduction of pain (*p* = 0.046).

Sleep interference {#sec017}
------------------

Patients in the gabapentin group reported more sleep problems, with significantly more sleep disturbances, awakening with shortness of breath or headache, sleep inadequacy, and worse score on the Sleep Problems Index ([Table 4](#pone.0217335.t004){ref-type="table"}).

10.1371/journal.pone.0217335.t004

###### Sleep problems and quality of life at week -12 in the two groups.
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                                        Gabapentin     Placebo     p-Value
  ------------------------------------- -------------- ----------- -------------
  **MOS-Sleep **                                                   
  Sleep disturbance                     32.7±21.7      22.8±26.6   **0.028**
  Snoring                               49.7±33.4      46.2±41.3   0.759
  Awakens short of breath or headache   16.1±25.5      5.0±12.6    **0.032**
  Sleep adequacy                        70.3±26.2      78.7±26.2   **0.005**
  Day-time somnolence                   35.9±22.5      24.2±20.1   0.126
  Sleep problems Index                  25.4±19.8      17.4±15.6   **0.038**
  **MOS-Sleep: optimal sleep**          n/N (%)        n/N (%)     0.392
  19/33 (57.6)                          20/42 (47.6)               
  **SF-12**                                                        
  Physical functioning                  44.9±11.8      51.5±7.5    **0.005**
  Role Physical                         26.1±4.1       28.7±2.3    **0.001**
  Role emotional                        18.7±5.2       21.8±2.6    **0.001**
  Mental Health                         45.3±10.2      53.7±8.1    **\<0.001**
  Bodily pain                           47.6±12.5      53.1±7.9    **0.026**
  General Health                        43.4±10.8      45.8±9.4    0.315
  Vitality                              50.9±10.7      54.8±9.4    0.105
  Social Functioning                    47.8±11.1      49.5±11.2   0.508
  Summary Scale Physical                44.1±9.9       47.8±6.6    0.061
  Summary Scale Mental                  38.1±9.0       42.6±6.5    **0.018**

Abbreviations: SD: standard deviation; SF-12: Short-Form 12; MOS-Sleep: Medical Outcomes Study.

Quality of life {#sec018}
---------------

The health status of patients, measured by SF-12, was worse in the gabapentin group than the placebo group ([Table 4](#pone.0217335.t004){ref-type="table"}). In particular, the gabapentin group had lower scores for physical functioning, role physical, role emotional, mental health, composite scale score, and bodily pain. We also analyzed quality of life and sleep problems, comparing patients with or without pain at week -12; statistically significant differences were observed in both physical and mental summary scale ([Table 5](#pone.0217335.t005){ref-type="table"}).

10.1371/journal.pone.0217335.t005

###### Sleep problems and quality of life in patient with pain score \>0 at week -12.
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                                        Patient without pain   Patient with pain score \>0   p-Value
  ------------------------------------- ---------------------- ----------------------------- -----------
  **MOS-Sleep **                                                                             
  Sleep disturbance                     26.5±25.2              30.4±22.1                     0.662
  Snoring                               46.2±37.9              57.8±38.0                     0.414
  Awakens short of breath or headache   8.4±19.0               20.0±24.5                     0.103
  Sleep adequacy                        74.2±29.7              81.1±16.9                     0.323
  Day-time somnolence                   27.8±20.3              39.3±30.1                     0.144
  Sleep problems Index                  20.6±18.2              23.0±16.5                     0.719
  **MOS-Sleep: optimal sleep**          n/N (%)                n/N (%)                       0.077
  31/62 (50.0)                          8/10 (80.0)                                          
  **SF-12**                                                                                  
  Physical functioning                  49.4±9.8               43.6±11.6                     0.162
  Role Physical                         28.0±3.1               24.9±4.3                      0.057
  Role emotional                        21.0±3.7               16.9±5.9                      **0.004**
  Mental Health                         51.0±9.5               43.8±10.8                     **0.034**
  Bodily pain                           51.7±9.2               44.2±16.0                     **0.026**
  General Health                        46.3±9.1               35.0±10.9                     **0.010**
  Vitality                              53.9±9.3               47.7±13.4                     0.074
  Social Functioning                    50.5±9.4               37.4±14.6                     **0.020**
  Summary Scale Physical                47.1±7.9               40.6±9.6                      **0.023**
  Summary Scale Mental                  41.7±7.8               34.1±5.4                      **0.004**

Abbreviations: SD: standard deviation; SF-12: Short-Form 12; MOS-Sleep: Medical Outcomes Study.

Patient global impression of change {#sec019}
-----------------------------------

When asked about their global impression of change using the PGIC, 29 of 32 patients (90.6%) in the gabapentin group reported much improvement, and 38 of 40 patients (95.0%) in the placebo group reported much improvement. This difference was not statistically significant.

Analgesic use {#sec020}
-------------

Analgesics were prescribed to 32.7% of the patients during the 12 week study period. There was less use of rescue analgesia in the gabapentin group (26% *vs*. 40%), but this was not statistically significant. The most prescribed drugs were analgesics and antipyretics (36%, ATC code: N02B), followed by non-steroidal anti-inflammatory drugs (13%, ATC code: M01A), and opioids (10.7%, ATC code: N02A).

Assessment of blinding {#sec021}
----------------------

At week-12, all patients were asked to guess the group to which they were randomized. Most patients in each group believed they were in the gabapentin group. The James index of patient blinding was 0.62 (95% CI: confidence interval (CI)95% (0.54 to 0.70), which was considered a successful random blinding.

Loss to follow-up {#sec022}
-----------------

Most of the patients lost to follow-up were men, and more patients were lost to follow-up in the gabapentin group (n = 16) than in the placebo group (n = 6). Most of these 16 patients in the gabapentin group abandoned the study between the first and the second visit (week-2 to week-4). Patients lost to follow-up reported less pain at week-4 (VAS 1.4 *vs*. 0.2) and this difference was statistically significant ([Table 6](#pone.0217335.t006){ref-type="table"}). Thus, patients who had mild pain or were pain-free withdrew from more frequently than those continuing the trial.

10.1371/journal.pone.0217335.t006

###### Characteristics of patients who completed the trial and were analyzed, and of patients who withdrew.
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                                            Analyzed       Drop-outs      p-value
  ----------------------------------------- -------------- -------------- ---------
  **Age**                                                                 
  \<65 years                                35/75 (46.7)   16/23 (69.6)   0.077
  65--84 years                              39/75 (52.0)   6/23 (26.1)    
  \>85 years                                1/75 (1.3)     1/23 (4.3)     
  Mean age (SD)                             65.6±10.6      64.2±11.8      0.583
  Women                                     47/75 (62.7)   7/23 (30.4)    0.007
  Mean BMI (kg/m^2^) (SD)                   28.0±5.5       27.7±4.2       0.888
  **HZ Location**                                                         
  Thorax                                    36/75 (48.0)   9/23 (39,1)    0.330
  Abdomen                                   8/75 (10.7)    6/23 (26.1)    
  Extremities                               15/75 (20.0)   4/23 (17.4)    
  Other                                     16/75 (21.3)   4/23 (17.4)    
  **SF-12** Mean (SD)                                                     
  Physical functioning                      47.3±11.5      46.9±11.7      0.925
  Role Physical                             27.4±3.4       26.4±3.9       0.454
  Role emotional                            19.8±4.5       22.5±0.1       0.081
  Mental Health                             49.4±11.9      52.3±7.4       0.476
  Bodily pain                               48.7±11.7      52.9±10.3      0.310
  General Health                            42.6±11.5      42.5±8.1       0.994
  Vitality                                  54.1±11.9      52.2±8.9       0.656
  Social functioning                        49.4±10.2      51.0±8.9       0.669
  Summary Scale Physical                    44.7±8.5       44.3±10.4      0.898
  Summary Scale Mental                      41.1±9.6       43.4±5.8       0.474
  **MOS- Sleep** Mean (SD)                                                
  Sleep disturbance                         34.3 ±28.8     32.6±26.3      0.864
  Snoring                                   50.4±38.8      55.0±38.2      0.752
  Awakening with short breath or headache   9.3±18.9       4.4±8.8        0.450
  Sleep adequacy                            71.5±29.7      64.4±36.1      0.514
  Day-time somnolence                       32.5±26.7      26.7±17.3      0.434
  Sleep Problems Index I                    24.8 ±21.4     25.9±17.1      0.880
  Sleep Problems Index II                   27.2±21.2      26.1±16.0      0.877
  **MOS Sleep: optimal sleep**              39/75 (52.0)   5/9 (55.6)     0.840
  **VAS pain** Mean (SD)                                                  
  VAS-pain at baseline                      6.8±1.9        6.7±1.7        0.851
  VAS-pain at week 1                        3.8±2.8        2.2±2.1        0.071
  VAS-pain at week 4                        1.4±2.0        0.2±0.4        0.001
  VAS-pain at week 6                        0.7±1.5        0.6±1.2        0.920

Abbreviations: BMI: Body Mass Index; VAS: visual analogic scale; SD: standard deviation; SF-12: Short-Form 12; MOS- Sleep: Medical Outcomes Study.

Safety {#sec023}
------

There were two severe adverse events during follow-up. One patient had a stroke and one patient had syncope and trifascicular heart block. Both events were in the gabapentin group and both patients were successfully treated. Neither event was considered related to gabapentin use.

Discussion {#sec024}
==========

We found no evidence that gabapentin prevented PHN when added to the usual treatment for HZ. Some evidence suggests that attenuation of pain during the acute phase of HZ might prevent PHN\[[@pone.0217335.ref031]\], and that gabapentin attenuates neuropathic pain by acting on the central and peripheral nervous system\[[@pone.0217335.ref032]\], both of which are damaged by the HZ infection. Therefore, we hypothesized that addition of gabapentin to the usual HZ treatment might provide better control of pain and reduce the incidence of PHN. Our results are inconsistent with this hypothesis.

The efficacy of gabapentin for the treatment of PHN is well established and there is also evidence that it improves patient quality of life, mood and sleep\[[@pone.0217335.ref011]\]. Typical gabapentin treatment begins at 300 mg/day and increases to 3600 mg/per day if necessary\[[@pone.0217335.ref033]\]. A recent Cochrane review reported that among patients taking gabapentin at doses higher than 1200 mg/day, there was a substantial effect on PHN-related pain (50% or more reduction in pain) in 32% of patients, and a moderately beneficial effect (30% or more reduction in pain) in 46% of patients\[[@pone.0217335.ref034]\]. However, these therapeutic dose levels are rarely achieved, and one estimate is that only 14% of patients receive a minimally effective dose of gabapentin\[[@pone.0217335.ref035]\]. Moreover, a 10 week titration period may be necessary to achieve these high doses\[[@pone.0217335.ref035]\]. Our results indicated that 27.3% of the participants reached the maximal dose of gabapentin. However, gabapentin was less effective than placebo at doses as high as 1800 mg, even though we used a rapid titration regimen to achieve a better pain control during the acute phase of HZ.

Another study that evaluated the efficacy of gabapentin during the acute herpetic infection phase had results similar to ours\[[@pone.0217335.ref036]\]. This RCT examined 120 participants with HZ within 4 days of rash onset and with pain scores of 4 on a 10-point Likert scale. In this study, 60 patients were randomized to receive 900 mg gabapentin (300 mg *tid*). The results indicated that the two groups had no significant differences of mean pain scores at each point of the trial, nor in the incidence of PHN (defined as a persistent pain score of 4 or more) after 12 weeks.

An open label pilot study of 133 patients who received gabapentin up to 3600 mg/day during the acute phase of HZ, reported a lower incidence of PHN relative to previously published data of patients not receiving gabapentin\[[@pone.0217335.ref037]\]. However, this study had no control group, so the clinical significance of the results is questionable.

Another RCT reported that when gabapentin is given during the acute phase of HZ infection, it provided no more relief from pain than a placebo at 4 weeks since rash onset\[[@pone.0217335.ref038]\]. Nevertheless, other authors reported beneficial effects of gabapentin on acute herpetic pain\[[@pone.0217335.ref039]--[@pone.0217335.ref041]\].

We also found that gabapentin did not improve QoL (measured by the SF-12) or sleep quality (measured by the MOS- sleep scale). This is similar to the results of a previous trial, which reported that gabapentin had no significant effect on Dermatological Quality of Life scores \[[@pone.0217335.ref036]\]. In our study, patients who received gabapentin had significantly poorer scores in the SF-12 domains of physical functioning, role physical, role emotional, mental health, and bodily pain. In addition, patients taking gabapentin had significantly poorer scores for sleep disturbance, sleep adequacy, and awakening with shortness of breath or a headache.

There were no significant safety concerns during our trial. Dizziness, somnolence, and abdominal pain were the most common adverse effects, similar to other trials of gabapentin. Only 3 patients in the gabapentin group withdrew consent due to drug-related adverse effects.

We found that gabapentin had no effect on acute pain during an HZ infection. These results are important, because gabapentin is recommended during the acute phase of HZ\[[@pone.0217335.ref021]\]. Clinicians must be aware of the side effects of gabapentin, such as dizziness, sedation, worsening of cognitive impairment, and ataxia, and the growing evidence that some patients may abuse misuse gabapentin due to its euphoric effects\[[@pone.0217335.ref042]\]. Furthermore, older patients are more likely to receive long-term treatments and polypharmacy, so extra caution is needed to avoid adverse interactions in this group.

An estimated 1 of 3 people develop HZ at some time during their lives\[[@pone.0217335.ref043]\]. When established, PHN is often very difficult to treat, and typically requires a multidisciplinary approach. As far as we know, there is no evidence that any therapy can prevent PHN after the onset of HZ. Vaccination seems to be key for prevention of HZ, and implicitly PHN. Recently, the Advisory Committee on Immunization Practices recommended vaccination for immunocompetent adults aged ≥50 years, preferably with the recombinant zoster vaccine and irrespective of prior receipt of any varicella vaccine or zoster live vaccine\[[@pone.0217335.ref044]\]. Despite the widespread availability of the live VZV vaccine, Centers for Disease Control and Prevention estimated that only 33% of adults older than 60 years had received HZ vaccine in the United States\[[@pone.0217335.ref044]\].

One strength of our study is that we examined the effectiveness of masking by asking all patients to guess whether they received gabapentin or the placebo. Most patients in the placebo group believed they were assigned to the gabapentin group. Another strength of our study is that its setting was in primary care offices, the type of health care facility most visited by patients. Providing an inexpensive and established therapy for pain control during the acute phase of HZ and for prevention of PHN in primary care is especially important, due to the limited accessibility to other analgesic therapies, such as sympathetic nerve blocks and pulsed radiofrequency electrical stimulation.

However, our trial had several limitations. First, we had a lower rate of recruitment. To achieve the recruitment target, based on our calculations of sample size, we extended the inclusion period an additional 6 months. We also included more primary health care centers than originally planned, as well as an off-hours primary care service and the emergency centers of two hospitals. We sent quarterly e-mail reminders describing the project inclusion criteria to all the collaborating centers, and also sent biannual updates. Other studies also reported difficulties in recruiting patients with acute HZ\[[@pone.0217335.ref045]\]. Nevertheless, our results must be interpreted carefully due to the smaller than expected sample size.

Secondly, in the gabapentin group 10 of 98 patients were lost to follow up and 6 participants withdrew consent. However, we attempted to reduce the possibility of attrition bias by performing an intention to treat analysis.

Conclusion {#sec025}
==========

Our results provide no evidence that gabapentin prevented PHN. However, further studies with larger sample sizes are needed to confirm the effect of gabapentin on prevention of PHN.
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